TL;DR
The global fallout from Amgen's compromised rare-disease drug Tavneos has escalated rapidly with a European revocation recommendation, triggering an immediate commercial land-grab by rival immunotherapies. At the same time, the FDA has granted accelerated approval to Vera Therapeutics' first-in-class dual inhibitor for progressive kidney disease. Meanwhile, public health officials are battling a historic, explosive parasite outbreak in Michigan alongside a multi-state E. coli recall linked to frozen berries.
European Market Upheaval Following the Tavneos Collapse
The collapse of Amgen’s scientific foundation has triggered a swift regulatory eviction from the European market, opening a massive commercial vacuum for rival immunology pipelines.
"InflaRx is preparing for discussions with regulators in Europe over two drugs that could provide an alternative to patients treated with Amgen’s Tavneos (avacopan), which is set to be removed from the EU market for the rare blood vessel inflammation disease ANCA-associated vasculitis (AAV)." — amgen-tavneos-eu-revocation-us-fda-extension
Building directly on the clinical crisis described in our last report, the European Medicines Agency's Committee for Medicinal Products for Human Use recommended revoking Tavneos's marketing authorization on June 26, 2026 EMA recommends revoking marketing authorisation for Tavneos. This regulatory shift has immediately prompted competitors like InflaRx to pivot their anti-C5a assets—such as vilobelimab—to capture the vulnerable European market, while Amgen races against a July 29, 2026, FDA deadline to submit independent data in a last-ditch effort to preserve its U.S. presence amgen-tavneos-eu-revocation-us-fda-extension.
What to watch: Watch whether InflaRx can successfully accelerate regulatory discussions in Europe to transition patients from Tavneos to vilobelimab amgen-tavneos-eu-revocation-us-fda-extension.
Accelerated Approval Shakes Up the Autoimmune Kidney Market
Regulatory pathways are opening rapidly for dual-targeting biologics in progressive kidney disease, introducing fierce competition to a crowded autoimmune market.
"TRUTAKNA is the first and only available therapy that binds both B-cell activating factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), addressing the immunological drivers at the source of IgA nephropathy (IgAN)." — vera-therapeutics-trutakna-fda-accelerated-approval-igan
The FDA's accelerated approval of Vera Therapeutics' Trutakna on July 7, 2026, validates a novel dual-inhibition mechanism that achieved a 46% reduction in proteinuria during clinical testing Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™. However, because this accelerated approval relies on surrogate biomarkers, Vera must still deliver positive long-term kidney function data later this year to secure its permanent market position vera-therapeutics-trutakna-fda-accelerated-approval-igan.
What to watch: Watch for the release of blinded, placebo-controlled kidney function data in the third quarter of 2026 to verify Trutakna's long-term therapeutic benefits vera-therapeutics-trutakna-fda-accelerated-approval-igan.
Severe Foodborne Pathogen Outbreaks Strike the Midwest and Southeast
Foodborne pathogen outbreaks are spiking sharply across the United States, challenging public health investigators to trace contamination sources before cases multiply.
"As of July 6, the state has received reports of over 700 cases since June 22, along with 36 hospitalizations, the Michigan Department of Health and Human Services (MDHSS) told Ars Technica on Tuesday." — cyclosporiasis-michigan-multistate-outbreak-2026
The sudden explosion of Cyclospora cayetanensis in Michigan, alongside a multi-state E. coli O145:H28 outbreak linked to recalled frozen blueberries that has caused 12 confirmed illnesses, highlights how quickly imported or distributed produce can spark widespread health crises Frutas y Hortalizas del Sur S.A. Initiates Recall of Frozen GreenWise Organic IQF Blueberries Due to Potential E. coli O145 Contamination. With no clear agricultural source identified yet for the Michigan parasite, local and federal agencies are racing against time to prevent further spread of these debilitating infections cyclosporiasis-michigan-multistate-outbreak-2026.
What to watch: Watch whether federal investigators can pinpoint the exact agricultural source of the Michigan Cyclospora outbreak to stem the historic surge cyclosporiasis-michigan-multistate-outbreak-2026.
What surprised us
- A historic parasite outbreak has hit Michigan with unprecedented force. The state has racked up over 700 cases in just two weeks—exploding past its typical annual average of only 50 cases cyclosporiasis-michigan-multistate-outbreak-2026
.
- Competitors did not wait for the ink to dry on Tavneos's European downfall. Within four days of the EMA recommending revocation, InflaRx publicly launched a strategy to pivot its anti-C5a pipeline to fill the impending market void amgen-tavneos-eu-revocation-us-fda-extension
.
- Frozen blueberries imported from Chile managed to harbor a dangerous E. coli strain. The contamination survived freezing and was distributed across eight southeastern states, defying the typical expectation that frozen fruit is a low-risk product category e-coli-frozen-blueberries-publix-multistate-outbreak-2026
.